USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Compusniff, LLC
Address:
Compusniff, Llc
575 Thornberry Ave
Cincinnati, OH 45231 0275
Phone:
(513) 772-3772
URL:
N/A
EIN:
311609265
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,247,761.00 9
SBIR Phase II $734,389.00 1

Award List:

IMPROVED ELECTRONIC WARFARE (EW) RESPONSE TIMES

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$49,845.00
Agency / Branch:
DOD / NAVY
Principal Investigator:
N Mcneill/g Anderson
Abstract:
This program provides a comprehensive analysis of current computeraided signal pattern recognition techniques and the application of artificial neural networks (neuronets) to the development of signal pattern recognition algorithms for tactical naval communications countermeasures. rf communications… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Robert C. Gesteland
Abstract:
N/a

Development of a non-living subunit rotavirus vaccine

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$117,500.00
Agency:
HHS
Principal Investigator:
Anthony H. Choi
Abstract:
DESCRIPTION (Provided by Applicant): Rotavirus disease in infants causes nearly one million deaths worldwide and costs the United States 1.5 billion dollars annually. In 1999, the only FDA-approved live-oral rotavirus vaccine, which was implicated in causing bowel obstruction, was… More

FSH Receptor Antisense Strategy for Contraception

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
James P. Leyda
Abstract:
DESCRIPTION (Scanned from the applicant's description): A new form of chemical contraceptive that has greater ease of use, more prolonged actions and a different profile of side effects than existing steroidal contraceptives would be welcomed by many women. A compound that… More

NOVEL OLIGOPEPTIDES AS TOPICAL SKIN LIGHTENING AGENTS

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
James P. Leyda
Abstract:
DESCRIPTION: (Verbatim) - Hyperpigmentary skin disorders affect several millions of people worldwide and are often the cause of social, life style and emotional problems. These disorders include solar lentigines (liver spots), vitiligo, freckles, and darkening of grafted… More

MICROELECTRODES FOR ENVIRONMENTAL MONITORING

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$356,493.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant):Remediation of Superfund and other hazardous waste sites requires the significant use of monitoring procedures to ensure that environmental conditions required for bioremediation or chemical degradation of specific toxicants are present, and to verify that… More

SNIFF MAGNITUDE RATIO AS A MEASURE OF OLFACTORY ACUITY

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
Smell loss is a health and safety problem for millions of Americans. Assessment of smell function is not routinely available. Our SBTR Phase I grant demonstrated the feasibility of a new test of olfactory function, the sniff magnitude test. The test performed well in reliability and validity… More

Needle-Free Delivery of Subunit Rotavirus Vaccines

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$125,499.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Rotavirus is the most common cause of severe gastroenteritis in infants causing nearly 1 million deaths worldwide and costing the United States 1.5 billion dollars annually. The only FDA-approved rotavirus vaccine was withdrawn in 1999 because of its association… More

Evaluation of rotavirus vaccines in a primate model

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$298,424.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Rotavirus causes severe diarrhea in infants resulting in approximately 600,000 deaths worldwide and costing the United States 1.5 billion dollars annually. The only FDA-approved rotavirus vaccine was withdrawn in 1999 because of its association with… More

Regulatory approval for the Sniff Magnitude Test

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$734,389.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The overarching goal of the current SBIR Phase II project is to further develop and commercialize the Sniff Magnitude Test (SMT) so it can be used to better evaluate olfactory loss in humans. The SMT is based on the reflex-like reduction in sniffing that is… More